Appointment as a UNSW Scientia Professor recognises outstanding research contributions and leadership, and is the University’s highest academic accolade.
Greg joined the Kirby Institute in 1995, and following initial research in HIV including a PhD on HIV-related opportunistic infections, he moved into hepatitis C epidemiology and clinical research. His early hepatitis C research defined many aspects of the natural history, including spontaneous viral clearance and liver disease progression. He has established an international leading research program focussing on hepatitis C therapeutic and elimination strategies, particularly among people who inject drugs. He las led many national and international hepatitis C clinical trials, and played a leading role in the 2016 PBS listing of direct-acting antiviral therapy. These highly curative and well tolerated therapies have been widely available since March 2016, with more than 60,000 Australians living with hepatitis C infection initiating treatment.
Congratulations Scientia Professor Greg Dore on this well-deserved appointment!